Experiences with
Xtandi2,107 public posts
Want to take advantage of all our features? Just log in!
or
enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
FDA previously approved enzalutamide for patients with castration-resistant prostate cancer.